Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma - Takeaways - MDSpire

Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma

  • By

  • Carmina Muñoz Bastidas

  • Mario Tapia Tapia

  • Andrés Calva López

  • Vanessa Talavera Cobo

  • Juan Colombas Vives

  • Eduardo Miraval Wong

  • Cristina Gutiérrez Castané

  • Francisco Javier Ancizu Marckert

  • Marcos Torres Roca

  • Luis Labairu Huerta

  • Fernando Diez-Caballero Alonso

  • José Enrique Robles García

  • Felipe Villacampa Aubá

  • Daniel González Padilla

  • Bernardino Miñana López

  • Daniel Sánchez Zalabardo

  • October 29, 2024

  • 0 min

Share

  • 1

    TFE3-rearranged renal cell carcinoma (RCC) is classified as a distinct molecular subtype in the 2022 WHO classification.

  • 2

    The incidence of TFE3-rearranged RCC is low, accounting for 1-4% in adults and 20-75% in pediatric cases.

  • 3

    TFE3 rearrangement is an independent prognostic factor associated with a higher recurrence rate compared to clear cell RCC.

  • 4

    Immunohistochemistry (IHC) is commonly used for diagnosis, but fluorescence in situ hybridization (FISH) is the gold standard.

  • 5

    Patients with TFE3-rearranged RCC have shorter progression-free survival compared to those with clear cell RCC.

Original Source(s)

Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma

  • by Carmina Muñoz Bastidas, Mario Tapia Tapia, Andrés Calva López, Vanessa Talavera Cobo, Juan Colombas Vives, Eduardo Miraval Wong, Cristina Gutiérrez Castané, Francisco Javier Ancizu Marckert, Marcos Torres Roca, Luis Labairu Huerta, Fernando Diez-Caballero Alonso, José Enrique Robles García, Felipe Villacampa Aubá, Daniel González Padilla, Bernardino Miñana López, Daniel Sánchez Zalabardo

  • October 29, 2024

Related Content

Assessment of the effectiveness and safety of anti-VEGF/VEGFR monotherapy versus its combination with immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma: a network meta-analysis

Kidney Cancer Updates - GU Oncology Cancer Highlights: ESMO 2024

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2024.

  • November 4, 2024

  • 1 min
Correction: Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis